

## II. REFERENCES

- A More Ethical Pizza. (2003, April 17). *The Washington Post*, p. A22.
- Abboud, L. (2004, August 3). Lilly plans broad access to results on its drug tests. *The Wall Street Journal*, p. B1.
- Accreditation Council for Continuing Medical Education. (2004, September 28). *ACCME member organizations approve 2004 updated standards for commercial support*. Retrieved November 15, 2004 from [http://www.accme.org/index.cfm/fa/news.detail/News/.cfm/news\\_id/cd9838e9-5e93-4e84-9eec-bda5d4333cc5.cfm](http://www.accme.org/index.cfm/fa/news.detail/News/.cfm/news_id/cd9838e9-5e93-4e84-9eec-bda5d4333cc5.cfm)
- Adams, C. (2002, February 15). FDA will pay doctors for views on TV drug ads. *The Wall Street Journal*, p. B1.
- Albee, G. W. (2002). Just say no to psychotropic drugs!. *Journal of Clinical Psychology*, 58, 635-648.
- Albee, G.W. (2002). Mad in America: Bad science, bad medicine, and the enduring mistreatment of the mentally ill. [Review of the book *Mad in America: Bad science, bad medicine, and the enduring mistreatment of the mentally ill*]. *Journal of Community & Applied Social Psychology*, 12, 444-450.
- American Medical Association. (1998). *Ethical Opinions and Guidelines: E-8.062 Gifts to physicians from industry*. Chicago, IL: Author. Retrieved November 15, 2004 from <http://www.ama-assn.org/ama/pub/category/4001.html>
- American Medical Association. (2004). *AMA (Gifts to phys cme) frequently asked questions*. Chicago, IL: Author. Retrieved November 15, 2004 from <http://www.ama-assn.org/ama/pub/category/13394.html>
- American Nurses Association. (1994). *Position statement: Guideline for commercial support for continuing nursing education*. Retrieved November 15, 2004 from <http://nursingworld.org/readroom/position/educate/edsupprt.htm>
- Angell, M. (2004). *The truth about the drug companies: How they deceive us and what to do about it*. New York: Random House.
- Antonuccio, D. O., Danton, W. G., & McClanahan, T. M. (2003). Psychology in the prescription era: Building a firewall between marketing and science. *American Psychologist*, 58, 1028-1043.
- Appleby, J. (2001, April 27). Drugmakers bankroll ethics guidelines on 'freebies': AMA effort intends to remind doctors of rules for accepting handouts. *USA Today*, p. B01.
- Appleby, J. (2001, May 16). Sales pitch: Drug firms use perks to push pills, companies ply doctors to write prescriptions. *USA Today*, p. B01.
- Associated Press. (2003, January 31). FDA clarifies guidelines for approval of drugs, devices. *The Washington Post*, p. A12.
- Backer, E. L., Lesback, J. A., Van Tonder, R. J. N. & Crabtree, B. F. (2000). The value of pharmaceutical representative visits and medication samples in community-based family practices. *Journal of Family Practice*, 49, 811-816.
- Barry, P. (2004,). Prescription drugs: The insiders. *AARP Bulletin Online*, November. Retrieved November 12, 2004 from <http://www.aarp.org/bulletin/prescription/Articles/a2004-10-27-insiders.html>

**This report has been received by the APA Board of Directors and provided to the APA Council of Representatives as information. It has not been adopted as APA policy by the APA Council and therefore does not commit APA to the activities or opinions described.**

- Beder, S. (2002). *Global spin: The corporate assault on environmentalism*. White River Junction, VT: Chelsea Green Publishing Company.
- Bero, L.A. (1999). Accepting commercial sponsorship: disclosure helps – but is not a panacea. *BMJ*, 319, 653-4.
- Bero, L.A. (2003, July). *Risky business: Tobacco industry manipulation of scientific research*. Paper presented at the Center for Science in the Public Interest Conference, Conflicted Science: Corporate Influence on Scientific Research and Science-Based Policy, Washington, DC.
- BMJ press releases regarding marketing influences on science. (2003, May 31). Retrieved May 31, 2003 from <http://bmj.com>
- Bodenheimer, T. (2000). Uneasy alliance: Clinical investigators and the pharmaceutical industry. *The New England Journal of Medicine*, 342, 1539-1544.
- Bodenheimer, T. & Collins, R. (2001, March 15). The ethical dilemma of drugs, money, medicine. *The Seattle Times*, p. B7.
- Bodil, A-N., Chen, W., Gluud, C., & Kjaergard, L. L. (2003). Association of funding and conclusions in randomized drug trials: A reflection of treatment effect of adverse events. *JAMA*, 290, 921-928.
- Bok, Derek. (2003, April 4). Academic values and the lure of profit. *The Chronicle of Higher Education*, 49, p. B7.
- Boyd, E. A. & Bero, L. A. (2000). Assessing faculty financial relationships with industry: A case study. *JAMA*, 284, 2209-2214.
- Breitstein, J. & Shalo, S. (2001). Insider profile: Ethical instigator. *Pharmaceutical Executive*, June, 134.
- Brubaker, W. (2002, January 19). Drug firms lavish pricey gifts on doctors: Ethics debated as freebies flow. *The Washington Post*, p. E01.
- Burton, R. (2003). U.S. wants Australia to modify its cheap drugs scheme as part of trade deal. *BMJ*. Retrieved March 31, 2003 from <http://bmj,bmjournals.com>
- Caplan, A. (1997) Medical ethic reaches the cutting edge [Review of the book *Conflicts of interest in clinical practice and research*]. *The Lancet*, 349, 962.
- Caplan, A. (1999). The birth of bioethics [Review of the book *The birth of ethics*] *JAMA*, 281, 849-850.
- Castleman, B. (2003, July). *The asbestos industry's assault on science and society*. Paper presented at the Center for Science in the Public Interest Conference, Conflicted Science: Corporate Influence on Scientific Research and Science-Based Policy, Washington, DC.
- Center for Science in the Public Interest. (2003) *Lifting the veil of secrecy: Corporate support for health and environmental professional associations, charities, and industry front groups*. Washington, DC: Author.
- Center for Science in the Public Interest. (2003, July 3). *Poll: Science & money don't mix*. (Press Release). Washington, DC: Author.
- Choudhry, N. K., Stelfox, H. T. & Detsky, A.S. (2002). Relationship between authors of clinical practice guidelines and the pharmaceutical industry. *JAMA*, 287, 612-617.
- Consortium aims to improve protection of human research subjects. (2002, January 29). *ScienceDaily Magazine*. Retrieved June 6, 2002 from <http://www.sciencedaily.com/releases/2002/01/020129074537.htm>

**This report has been received by the APA Board of Directors and provided to the APA Council of Representatives as information. It has not been adopted as APA policy by the APA Council and therefore does not commit APA to the activities or opinions described.**

- Coyle, S. L. (for the Ethics and Human Rights Committee, American College of Physicians-American Society of Internal Medicine). (2002, March 5). Physician-industry relations. Part 1: individual physicians (Position paper). *Annals of Internal Medicine*, 136, 396-402. Retrieved November 15, 2004 from <http://www.annals.org/cgi/reprint/136/5/396.pdf>
- Coyle, S. L. (for the Ethics and Human Rights Committee, American College of Physicians-American Society of Internal Medicine). (2002, March 5). Physician-industry relations. Part 2: organizational issues (Position paper). *Annals of Internal Medicine*, 136, 403-406. Retrieved November 15, 2004 from <http://www.annals.org/cgi/reprint/136/5/403.pdf>
- Crossen, C. (2001, January 3). The treatment: A medical researcher pays for challenging drug-industry funding—he said antibiotics weren't good for kids' earaches, his peers found otherwise—now, his view gains ground. *The Wall Street Journal*, p. A1.
- Dana, J. & Lowenstein, G. (2003). A social science perspective on gifts to physicians from industry. *JAMA*, 290, 252-255.
- Davidoff, F., DeAngelis, C. D., Drazen, J. M., Hoey, J., Hojgard, L., Norton, R., et al. (2001). Sponsorship, authorship and accountability. *New England Journal of Medicine*, 345. Retrieved December 10, 2002 from <http://mindfully.org/Health/Sponsorship-Accountability-NEJM.htm>
- Dember, A. (2001, May 20). Drug firms woo doctors with perks: Billions spent in bid to gain brand loyalty. *The Boston Globe*, p. A1.
- Donaldson, T. (2001). The business ethics of bioethics consulting. *Hastings Center Report*, March-April, 12-14.
- Draper, E. (2003) *The company doctor: Risk, responsibility, and corporate professionalism*. New York: Russell Sage Foundation.
- Drug company influence on medical education in USA. (2000). *The Lancet*, 356, 781.
- Drummond, R. (2004). Trial registration: A great idea switches from ignored to irresistible. *JAMA*, 292, 1359-1362.
- Dougherty, M. J., Sweeney, Jr., H. A. & Iacono, A. M. (2000). Industry pays the doctor bill for escalating CME costs. *Medical Marketing & Media*, December, 88-96.
- Elliot, C. (2000). Pursued by happiness and beaten senseless: Prozac and the American dream. *Hastings Center Report*, March-April, 7-12.
- Elliot, C. (2001). Throwing a bone to the watchdog. *Hastings Center Report*, March-April, 9-11.
- Elliott, C. (2001). Pharma buys a conscience. *The American Prospect*, September 24-October 8, 16-20.
- Ernhart, C. B., Scarr, S. & Geneson, D. F. (1993). On being a whistleblower: The Needleman case. *Ethics & Behavior*, 3, 73-93.
- Ethical principles of psychologists and code of conduct. (2002). *American Psychologist*, 57, 1060-1073.
- Financial associations of authors. (2002). *New England Journal of Medicine*, 346, 1901-1902.
- Findlay, S. (1997, August 20). AMA rethinks endorsing line of consumer goods. *USA Today*, p. 03A.

**This report has been received by the APA Board of Directors and provided to the APA Council of Representatives as information. It has not been adopted as APA policy by the APA Council and therefore does not commit APA to the activities or opinions described.**

- Goldfinger, S. E. (1990, April 15). Position Paper, American College of Physicians: Physicians and the pharmaceutical industry. *Annals of Internal Medicine*, 112, 624-626.
- Gorner, P. (2000, October 29). Medicine's bible losing its aura of gospel truth. *Chicago Tribune*. Retrieved November 15, 2004 from <http://pqasb.pqarchiver.com/chicagotribune/>
- Greenberg, D. S., (2003). Conference deplors corporate influence on academic science. *The Lancet*, 362, 302-303. Retrieved on September 24, 2003 from [www.thelancet.com](http://www.thelancet.com)
- Greer, L. & Steinzor, R. (2002). Bad science. *The Environmental Forum*, January/February, 28-43.
- Hall, W. J. (2001, December). The ethical dilemma of accepting gifts from drug makers. *ACP-ASIM Observer*. Retrieved November 15, 2004 from <http://www.acponline.org/journals/news/dec01/president.htm>
- Hans, V. P. (2000). *Business on trial: The civil jury and corporate responsibility*. New Haven, CT: Yale University Press.
- Harris, G. (2004, November 4). Drug-safety reviewer says F.D.A. delayed Vioxx study. *The New York Times*. Retrieved November 4, 2004 from <http://www.nytimes.com/2004/11/10/business/10drug.html>
- Healy, M. (2002, February 6). Doctors acknowledge drug-firm contacts. *USA Today*, p. D08.
- Healy, M. (2003, July 10). Be wary of big money, health groups are warned: Corporate funding could skew research. *USA Today*, p. 6D.
- Hensley, S. (2002, January 21). AMA, prescription drug-makers agree ethics policy needs better implementation. *The Wall Street Journal*, p. B4.
- Hensley, S. (2002, December 4). When doctors go to class, industry often foots the bill: Lectures tend to feature pills but drug firms deny influence. *The Wall Street Journal*. Retrieved December 22, 2002 from <http://online.wsj.com>
- Holmer, A. F. (2001, April 18). Industry strongly supports continuing medical education. *JAMA*, 285, 2012-2014.
- Hooked on freebies. (2001, September 6). *St. Louis Post-Dispatch*, p. B6.
- Japsen, B. (2001, June 18). AMA weighs ending sale of doctor data to drug firms. *Chicago Tribune*. Retrieved November 15, 2004 from <http://pqasb.pqarchiver.com/chicagotribune/>
- Japsen, B. (2001, August 29). AMA prescribes low-gift diet: \$1 million effort seeks to reinforce ethics guidelines. *The Chicago Tribune*, p.1.
- Japsen, B. (2001, December 4). Doctors ask to keep prescribing secret: AMA data selling reaps \$20 million. *Chicago Tribune*. Retrieved November 15, 2004 from <http://pqasb.pqarchiver.com/chicagotribune/>
- Kassirer, J. P. & Angell, M. (1993). Financial conflicts of interest in biomedical research. *The New England Journal of Medicine*, 329. Retrieved December 10, 2002 from <http://www.nejm.org/hfa/financialconflicts.asp>
- Kaufman, M. (2002, June 14). Vt. requires firms to report gifts to doctors: Law prompted by concern about abuses, cost of drug companies' marketing. *The Washington Post*, p. A2.

**This report has been received by the APA Board of Directors and provided to the APA Council of Representatives as information. It has not been adopted as APA policy by the APA Council and therefore does not commit APA to the activities or opinions described.**

- Kaufman, M. (2003, April 26). FDA says it can take away drugs' prescription status. *The Washington Post*, A1, A6, A7.
- Kaufman, M. & Julien, A. (2000, November 14). The implications of corporate funding: When drug companies are paying the bills, what happens to researchers' objectivity and independence? The stakes are sickness or health, life or death. *Newsday*, p. C06.
- Kaufman, M. & Masters, B.A. (2004, November 18). FDA is flexing less muscle. *The Washington Post*. Retrieved November 18, 2004 from <http://www.washingtonpost.com/wp-dyn/articles/A58470-2004Nov17.html>
- Krimsky, S. (2003). *Science in the private interest: Has the lure of profits corrupted biomedical research?*. Lanham, MD: Rowman & Littlefield Publishers, Inc.
- Kranish, Michael (2002, December 22). FDA counsel's rise embodies U.S. shift. *The Boston Globe*. Retrieved December 26, 2002 from [www.bostonglobe.com](http://www.bostonglobe.com)
- Kritz, F. L. (2004, February 10). FDA on drugs: Less is more. *The Washington Post*, pp. F1, F4.
- Krueger, M. & Shalo, S. (2001). Common ground: A collaborative approach to clinical trial recruitment. *Pharmaceutical Executive*, May, 114-120.
- Lipman, J. (1990, January 22). Heart group's seal lacks full approval. *The Wall Street Journal*, p. B6.
- Lexchin, J. (2003). Pharmaceutical industry sponsorship and research outcome and quality: systematic view. *BMJ*, 326. Retrieved May 31, 2003 from <http://bmj.com/cgi/content/full/326/7400/1167>
- Maguire, P. (2001). Ethical issues in CME, clinical research. *ACP-ASIM Observer*, May. Retrieved November 15, 2004 from <http://www.acponline.org/journals/news/may01/ethicalprobs.htm>
- Mangan, K. S. (2003, August 14). Many medical professors who serve on review boards also have industry ties, study finds. *The Chronicle of Higher Education*. Retrieved August 14, 2003 from <http://chronicle.com/daily/2003/08/2003081402n.htm>
- Markowitz, G. & Rosner, D. (2003, July). *Deceit and denial in the lead industry*. Paper presented at the Center for Science in the Public Interest Conference, Conflicted Science: Corporate Influence on Scientific Research and Science-Based Policy, Washington, DC.
- Mayer, C. E. (2003, June 15). Today's lesson sponsored by ...: Corporate cash prizes aid schools, court customers. *The Washington Post*. Retrieved June 17, 2003 from <http://www.washingtonpost.com>
- Mayer, C. E. (2003, June 21). PTA turning to corporate sponsors for funds: Donation from Coca-Cola to national group opposed by some parents. *The Washington Post*. Retrieved June 25, 2003 from <http://www.washingtonpost.com>
- McCarthy, Michael. (2000). Medical education companies come under fire in USA. *The Lancet*, 356, 494.
- Medical journals plan to help researchers gain right to publish. (2001, August 6). *The Wall Street Journal*, p. B4.
- Medical licensure board will warn doctors not to accept gifts. (2001, March 25). *The Associated Press*.

**This report has been received by the APA Board of Directors and provided to the APA Council of Representatives as information. It has not been adopted as APA policy by the APA Council and therefore does not commit APA to the activities or opinions described.**

- Melander, H. (2003). Evidence b(i)ased medicine – selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. *BMJ*, 326. Retrieved May 31, 2003 from <http://bmj.com/cgi/contents/full/326/7400/1171>
- Michaels, D., Bingham, E., Boden, L., Clapp, R., Goldman, L.R., Hoppin, P., et al. Advice without dissent. *Science*, 298, 703.
- Mickleburgh, Rod. (2002, February 6). Study links doctors, drug firms: MDs who have ties through research funds or employment are urged to disclose them. *The Globe and Mail*, p. A8.
- Morin, K., Rakatansky, H. Riddick, Jr., Morse, L. J., O'Bannon III, J.M., Goldrich, M. S., et. al. (2002). Managing conflicts of interest in the conduct of clinical trials. *JAMA*, 287, 78-84.
- Morin, R. & Deane, C. (2003, April 8). Irked drug industry may pull tank funds. *The Washington Post*, p. A31.
- Moynihan, R. (2003, October 18). Cochrane at crossroads over drug company sponsorship. *BMJ*, 327, 924-926. Retrieved October 17, 2003 from <http://bmj.bmjournals.com>
- Moynihan, R. (2003). Who pays for the pizza? Redefining the relationship between doctors and drug companies. *BMJ*, 326. Retrieved May 31, 2003 from <http://bmj.com/cgi/full/226/7400/1189>
- Mundy, A. (2001). *Dispensing with the truth: The victims, the drug companies, and the dramatic story behind the battle over Fen-Phen*. New York: St. Martin's Press.
- Mundy, A. (2003, January/February). Hot flash, cold cash: How a once-respected woman's group went through The Change – with the help of drug industry money. *The Washington Monthly*, 35-39.
- Mundy, A. & Marcus, J. (2000, February). First, do no harm. *Boston Magazine*, 50-55.
- National Association of Attorneys General. (2004, May 13) *Settlement: Fifty attorneys general announce settlement with Pfizer over improper off-label drug marketing*. (Press release). Washington, DC: Author. Retrieved November 10, 2004 from <http://www.naag.org/issues/20040513-settlement-pfizer.php>
- Needleman, H. L. (1992). Salem comes to the National Institutes of Health: Notes from inside the crucible of scientific integrity. *Pediatrics*, 90, 977-981.
- Needleman, H. L. (1993). Reply to Ernhart, Scarr, and Geneson. *Pediatrics*, 3, 95-101.
- NIH rule defines conflict of interest for peer reviewers, codifies 1997 review criteria. (2004, January 8). *The Washington Fax*. Retrieved January 8, 2004 from <http://www.washingtonfax.com/p1/2004/20040108.html>
- Okie, S. (2001, August 30). AMA criticized for letting drug firms pay for ethics campaign. *The Washington Post*, p. A03.
- Ottaway, D.B. & Stephens, J. (2003, May 4). Nonprofit land bank amasses billions: Charity builds assets on corporate partnerships. *The Washington Post*. Retrieved June 12, 2003 from <http://nl.newsbank.com>
- Ottaway, D.B. & Stephens, J. (2003, May 5). On eastern shore, for-profit "flagship" hits shoals: Local ventures launched, foundered and failed. *The Washington Post*. Retrieved June 12, 2003 from <http://nl.newsbank.com>

**This report has been received by the APA Board of Directors and provided to the APA Council of Representatives as information. It has not been adopted as APA policy by the APA Council and therefore does not commit APA to the activities or opinions described.**

- Ottaway, D. B. & Stephens, J. (2003, May 5). Landing a big one: Preservation, private development. *The Washington Post*. Retrieved June 12, 2003 from <http://nl.newsbank.com>
- Ottaway, D.B. & Stephens, J. (2003, October 25). Land trust alliance is rewriting its ethical standards: Organization is responding to increased scrutiny of preservation practices. *The Washington Post*, p. A14.
- Pallarito, K. (2003, April 4). Canadian pharmacies offer U.S. druggists lucrative rewards for referrals. *Reuters Health*.
- Pear, R. (2002, December 25). Drug makers battle plan to curb rewards for doctors. *The New York Times*. Retrieved December 26, 2002 from <http://www.nytimes.com>
- Petersen, M. (2002, January 18). Merck is said to limit perks in marketing to physicians. *The New York Times*, p. C1.
- Petersen, M. (2003, August 3). Undisclosed financial ties prompt reproof of doctor. *The New York Times*. Retrieved August 3, 2003 from <http://www.nytimes.com/ref/membercenter/nytarchive.html>
- Petersen, M. (2003, August 22). Scientists urge journal policy on disclosures. *The New York Times*. Retrieved August 22, 2003 from <http://www.nytimes.com/ref/membercenter/nytarchive.html>
- Pharmaceutical Research and Manufacturing Association. (2002). *PhRMA code on interactions with healthcare professionals*. Washington, DC: Author.
- Physician prescribing data use in marketing will be scrutinized by AMA. (2000, December 11). *The Pink Sheet*, 62.
- Pisetsky, D. S., Hunder, G. G. & Gravalles, E. M. (2003). New policy on disclosure of interest for American College of Rheumatology journals. *Arthritis & Rheumatism*, 49, 149-150.
- Preeminent scientists protest Bush administration's misuse of science. (2004, February 28). Press release from the *American Academy for the Advancement of Science*.
- Regulators appear to be gearing up for new conflict of interest. (2000, August 7). *Washington Drug Letter*.
- Relman, A. S. (2001, April 18). Separating continuing medical education from pharmaceutical marketing. *JAMA*, 285, 2009-2012.
- Relman, A. S. (2001, September 22). Trust me, I'm a scientist (drug companies have too much control over medical research). *New Scientist*, 48.
- Relman, A.S. & Angell M. (2002, December 16). America's other drug problem: How the drug industry distorts medicine and politics. *The New Republic*, 27-41.
- Rennie, D. (2003, July). *Paying the piper, picking the tune: Drug companies and clinical researchers*. Paper presented at the Center for Science in the Public Interest Conference, Conflicted Science: Corporate Influence on Scientific Research and Science-Based Policy, Washington, DC.
- Resident physician and medical industry interactions: Guiding Principles*. (n.d.). Association of American Medical Colleges.
- Rochell, A. (1996, August 17). Cancer society sells its name to drug maker, citrus growers. *The Atlanta Journal-Constitution*, p. A01.

**This report has been received by the APA Board of Directors and provided to the APA Council of Representatives as information. It has not been adopted as APA policy by the APA Council and therefore does not commit APA to the activities or opinions described.**

- Schmid, R. E. (2004, January 24). NIH forming conflicts-of-interest panel. *Associated Press*. Retrieved January 24, 2004 from <http://yahoo.com/news>
- Seabrook, C. (1993, November 12). American Heart Association: Conference in Atlanta, drug makers fear reform plan could halt research. *The Atlanta Journal-Constitution*, p. A7.
- Seligman, K. (2003, May 19). Psychiatry convention begins in S.F.: Virtual reality tours of schizophrenic mind. *San Francisco Chronicle*. Retrieved June 13, 2003 from <http://www.nexis.com>
- Shapiro, D. (2004, January 20). Drug companies get too close for med school's comfort. *The New York Times*. Retrieved January 21, 2004 from <http://www.nytimes.com>
- Shogren, E. (2004, February 19). White House accused of science bias: The administration has censored and suppressed reports from U.S. agencies that don't adhere to party line, the group alleges. *The Los Angeles Times*, n.a.
- Shrader-Frechette, K. (2003, March). *Public citizenship and the duties of scientists: Avoiding the best science money can buy*. Paper presented at the 54<sup>th</sup> annual meeting of the American Institute of Biological Sciences, Washington, DC.
- Siegel, M. (2002, December 30). The hungry physician. *The Nation*. Retrieved December 22, 2002 from [www.thenation.com](http://www.thenation.com)
- Slanted?: FDA inquiry needed. (2003, May 2). *Charleston Gazette*. Retrieved May 13, 2003 from <http://www.wvgazette.com>
- Squires, S. (2003, August 25). Diet panel nominees questioned: Groups say some named have too close ties to food, drug industries. *The Washington Post*, A15.
- Stephens J. & Ottaway, D. B. (2003, May 4). Image is a sensitive issue. *The Washington Post*. Retrieved June 12, 2003 from <http://nl.newsbank.com>
- Stephens J. & Ottaway, D.B. (2003, May 5). How a bid to save a species came to grief. *The Washington Post*. Retrieved June 12, 2003 from <http://nl.newsbank.com>
- Stephens J. & Ottaway, D.B. (2003, May 5). The beef about the brand. *The Washington Post*. Retrieved June 12, 2003 from <http://nl.newsbank.com>
- Stephens J. & Ottaway, D.B. (2003, May 6). Nonprofit sells scenic acreage to allies at a loss: Buyers gain tax breaks with few curbs on land use. *The Washington Post*. Retrieved June 12, 2003 from <http://nl.newsbank.com>
- Stephens J. & Ottaway, D. B. (2003, June 14). Conservancy abandons disputed practices: Land deals, loans were questioned. *The Washington Post*. Retrieved June 17, 2003 from <http://www.washingtonpost.com/wp-dyn/articles/A57730-June14.html>
- Stern, A., Hunter, D. & Fisher, P. M. (2000). A sponsorship dilemma: The experts. *Hospitals & Health Networks*, 74, 26.
- Stern, C. (2003, June 20). WorldCom opponents in sync: D.C. firm helps organize protest. *The Washington Post*. Retrieved June 25, 2003 from <http://www.washingtonpost.com>
- Sunstein, C. R., Hastie, R., Payne, J. W., Schkade, D. A. & Viscusi, W. K. *Punitive damages: How juries decide*. Chicago: The University of Chicago Press.
- Sweeney, H. A. (2001). Medical Marshall plan: A prescription for industry's image problems. *Medical Marketing & Media*, December, 78-83.

**This report has been received by the APA Board of Directors and provided to the APA Council of Representatives as information. It has not been adopted as APA policy by the APA Council and therefore does not commit APA to the activities or opinions described.**

- Tanner, L. (2000, November 1). Medical experts attack drug companies' largess. *Portland Oregonian*, p. A02.
- Tanner, L. (2000, November 2). JAMA details doctor-drug company conflicts of interest. *The Associated Press*.
- Torassa, U. (2002, February 10). Doctors relationships with drug makers can make for bad medicine. *The San Francisco Chronicle*, p. E4.
- Tye, L. (2000, December 18). Psychotherapists increasingly turn to marketing tools. *The Boston Globe*, p. A1.
- Unger, M. (1991, June 21). Drug firm videos get FDA critique: Says public may be duped by videos. *Newsday*, 41.
- Vedantam, S. (2001, July 16). Drug ads hyping anxiety make some uneasy. *The Washington Post*. Retrieved June 13, 2003 from <http://www.nexis.com>
- Vedantam, S. (2002, May 26). Industry role in medical meeting decried: Symposia sponsored by pharmaceutical companies trouble some psychiatrists. *The Washington Post*. Retrieved June 12, 2003 from <http://nl.newsbank.com>
- Vedantam, S. (2003, June 11). Britain warns of Paxil's risk to children. *The Washington Post*, p. A14.
- Vedantam, S. (2003, August 30). Bush would add review layer for rules: Industry cheers science peer-appraisal plan, critics say it will discourage regulation. *The Washington Post*, p. A10.
- Vedantam, S. (2004, February 2). FDA panel to weigh safety of mood drugs for children: Some data link use of antidepressants, suicidal thoughts. *The Washington Post*, p. A 4.
- Waldholz, M. (1988, June 17). The cholesterol bandwagon: Food, drug, lab companies are mounting massive campaigns to spread their message. *St. Petersburg Times*, p. 1A.
- Waters, R. (2004, January 4). A suicide effect?: What parents aren't being told about their kids' antidepressants. *San Francisco Chronicle*. Retrieved from [sfgate.com/article.cgi?file=c/a/2004/01/04/CM118609.DTL](http://sfgate.com/article.cgi?file=c/a/2004/01/04/CM118609.DTL)
- Watkins, C. (2003). Characteristics of general practitioners who frequently see drug industry representatives: National cross sectional study. *BMJ*, 326. Retrieved May 31, 2003 from <http://bmj.com/cgi/contents/full/326/7400/1178>
- Wazana, A. (2000, January 19). Physicians and the pharmaceutical industry: Is a gift ever just a gift?. *JAMA*, 283, 373-380.
- Weiss, R. (2003, August 8). Bush misuses science, report says: Democrats say data are distorted to boost conservative policies. *The Washington Post*, p. A15.
- Weiss, R. (2003, October 30). NIH faces criticism on grants: Coalition assails 'sarmy projects'. *The Washington Post*, p. A21.
- Weiss, R. (2004, January 15). Peer review plan draws criticism: Under Bush proposal, OMB would evaluate science before new rules take effect. *The Washington Post*, p. A19.
- Weiss, R. (2004, January 23). NIH chief taps duo to review allegations: Conflict-of-interest claims to be studied. *The Washington Post*, p. A19.
- Westfall, J. M. (2000). Physicians, pharmaceutical representatives, and patients: Who really benefits?. *Journal of Family Practice*, 49, 817.

**This report has been received by the APA Board of Directors and provided to the APA Council of Representatives as information. It has not been adopted as APA policy by the APA Council and therefore does not commit APA to the activities or opinions described.**

Willman, D & Marino, J. (2004, January 23). NIH directors no longer drug firm consultants. *The Los Angeles Times*. Retrieved January 23, 2004 from <http://www.latimes.com/news/nationworld/nation/la-na-nih23jan23,1,904004.story?coll=la-home-headlines>

Zarembo, A. (2003, December 26). Exxon funded research into jury awards: Company cited studies to appeal damages, without saying it paid for them. *The Washington Post*, p. A20.

**This report has been received by the APA Board of Directors and provided to the APA Council of Representatives as information. It has not been adopted as APA policy by the APA Council and therefore does not commit APA to the activities or opinions described.**